Boehringer Ingelheim brings development ‘under one roof’ with €230m biologics centre
Boehringer Ingelheim has announced plans to invest €230m ($269m) in a Biologics Development Centre (BDC) at its R&D site in Biberach, Germany. The facility – set to launch in 2020 – will house analytical, process development, and manufacturing capabilities for biologics.
According to the Germany-headquartered firm, the site will ‘free up’ capacity for its contract manufacturing business: “In the BDC we will conduct development for biologics from both our research pipeline as well as biopharmaceutical contract manufacturing,” spokesperson Matthias Reinig told us.
“As overall development capacity will increase, more resources overall can be dedicated to contract manufacturing development,” he added.
The BDC will bring development activities – currently “spread over various places” at Biberach – together, Reinig explained: “With the BDC, they will locate under one roof while adding another 100 staff to further extend capacity.”
The investment is the latest in a series of biopharmaceutical facility expansions for Boehringer Ingelheim. In 2017, the firm broke ground on a €700m mammalian cell culture production plant in Vienna, Austria, and opened a contract biomanufacturing plant in Shanghai, China.
In addition, in July 2017, the firm announced plans to expand, upgrade, and increase headcount at its biologics manufacturing facility in Fremont, California.
